On Oct 25, major Wall Street analysts update their ratings for $Marinus Pharmaceuticals (MRNS.US)$, with price targets ranging from $3 to $3.
TD Cowen analyst Joseph Thome maintains with a hold rating.
Oppenheimer analyst Jay Olson maintains with a buy rating.
Truist Financial analyst Joon Lee maintains with a hold rating.
EF Hutton analyst Jason Kolbert initiates coverage with a buy rating, and sets the target price at $3.
JMP Securities analyst Jason Butler downgrades to a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Marinus Pharmaceuticals (MRNS.US)$'s main analysts recently are as follows:
Marinus Pharmaceuticals' oral ganaxolone in a Phase III study for tuberous sclerosis complex rare epilepsy did not achieve a significant difference in placebo-adjusted percent change. Despite this, there may still be potential for revenue generation in CDD, and if the stock's value remains low following an 80% decrease, an arbitrage opportunity could present itself.
Marinus Pharmaceuticals' recent Phase III trial of ganaxolone in tuberous sclerosis complex did not achieve the primary endpoint. This has led to concerns regarding the company's limited financial runway and the uncertain future direction following these results.
Marinus Pharmaceuticals' Phase III study of oral ganaxolone in tuberous sclerosis complex rare-epilepsy did not achieve the primary endpoint of reducing seizures. Analysts believe this outcome has led to a lack of immediate catalysts anticipated before 2025.
Marinus Pharmaceuticals' announcement regarding the Phase 3 study of ganaxolone in TSC not meeting its primary endpoint has prompted the company to explore strategic alternatives. This development eliminates the possibility of a Ztalmy label expansion which was anticipated to substantially enhance revenues beyond its use in CDD.
Here are the latest investment ratings and price targets for $Marinus Pharmaceuticals (MRNS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
